Literature DB >> 17305640

Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.

Kaarina Sundelin1, Karin Roberg, Reidar Grénman, Leif Håkansson.   

Abstract

BACKGROUND: Previous studies showed that many chemotherapeutic agents can induce immuno-suppression at therapeutic drug concentrations whereas low drug doses induce immuno-augmentation.
METHODS: The effect of low-dose cisplatin, interferon-alpha, and 13-cis retinoic acid on receptors involved in immune-mediated apoptosis (Fas/CD95), cell growth (epidermal growth factor receptor) and lymphocyte adhesion (intercellular adhesion molecule-1) was investigated in two oral cancer cell lines (UT-SCC-20A and UT-SCC-24A). Different methods for cell preparation were studied: mechanical and enzymatic detachment, and culture on chamber slides. Receptor expression was investigated using immunohistochemical staining. The amount of soluble and cell-bound Fas was determined with the ELISA technique, and the functional relevance of Fas expression, apoptosis induction, was analyzed.
RESULTS: Cisplatin enhanced cytoplasm and membrane staining for Fas in both cell lines. After cisplatin treatment, the amount of soluble Fas was increased in UT-SCC-20A cultures, but no effect was observed in the UT-SCC-24A cell line. Apoptosis, measured as enhanced caspase-3 activity, was induced by an agonistic Fas antibody (CH11) after cisplatin treatment in UT-SCC-24A cells.
CONCLUSIONS: Low-dose cisplatin treatment enhanced Fas expression in both cell lines and increased susceptibility to apoptosis in one of them.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305640     DOI: 10.1111/j.1600-0714.2006.00503.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  6 in total

Review 1.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Authors:  Sofia R Gameiro; Jorge A Caballero; James W Hodge
Journal:  Cancer Biother Radiopharm       Date:  2012-02-08       Impact factor: 3.099

3.  Vaccines as monotherapy and in combination therapy for prostate cancer.

Authors:  Julia Rotow; Sofia R Gameiro; Ravi A Madan; James L Gulley; Jeffrey Schlom; James W Hodge
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

Review 4.  Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.

Authors:  Jing Liu; Jie Zhao; Liang Hu; Yuchun Cao; Bo Huang
Journal:  Cell Mol Immunol       Date:  2011-03-21       Impact factor: 11.530

5.  Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.

Authors:  Sofia R Gameiro; Jorge A Caballero; Jack P Higgins; David Apelian; James W Hodge
Journal:  Cancer Immunol Immunother       Date:  2011-05-05       Impact factor: 6.968

6.  IFNα2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients--a preliminary study.

Authors:  Kalyan Kusum Mukherjee; Anamika Bose; Diptendu Ghosh; Koustav Sarkar; Shyamal Goswami; Smarajit Pal; Jaydip Biswas; Rathindranath Baral
Journal:  Indian J Med Res       Date:  2012-07       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.